BRCA1 and ovarian carcinoma: These findings align with current NCCN guidelines (13), which recommend BRCA1/2 testing in all high-grade epithelial ovarian cancers, including OCS, and the use of PARP inhibitors as maintenance therapy in mutation-positive cases.